Characterizing driving behaviors in multiple sclerosis: Cognition versus disease severity

Background: The measurement of health state utility values (HSUVs) for a representative sample of Australian people with multiple sclerosis (MS) has not previously been performed. Objectives: Our main aim was to quantify the HSUVs for different levels of disease severities in Australian people with MS. Method: HSUVs were calculated by employing a ‘judgement-based’ method that essentially creates EQ-5D-3L profiles based on WHOQOL-100 responses and then applying utility weights to each level in each dimension. A stepwise linear regression was used to evaluate the relationship between HSUVs and disease severity, classified as mild (Expanded Disability Status Scale (EDSS) levels: 0–3.5), moderate (EDSS levels: 4–6) and severe (EDSS levels: 6.5–9.5). Results: Mean HSUV for all people with MS was 0.53 (95% confidence interval (CI): 0.52–0.54). Utility decreased with increasing disease severity: 0.61 (95% CI: 0.60–0.62), 0.51 (95% CI: 0.50–0.52) and 0.40 (95% CI: 0.38–0.43) for mild, moderate and severe disease, respectively. Adjusted differences in mean HSUV between the three severity groups were statistically significant. Conclusion: For the first time in Australia, we have quantified the impact of increasing severity of MS on health utility of people with MS. The HSUVs we have generated will be useful in further health economic analyses of interventions that slow progression of MS.

Download Full-text

PRM115 Modelling the Relationship Between Disease Severity and Utility in Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2012.08.1578 ◽

2012 ◽

Vol 15 (7) ◽

pp. A481

Author(s):

E. Fogarty ◽

C. Walsh ◽

S. Grehan ◽

S. Schmitz ◽

C. McGuigan ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Severity ◽

The Relationship

Download Full-text

0573 The multiple sclerosis severity score: Optimising the use of cross sectional disability to measure disease severity

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(05)80939-6 ◽

2005 ◽

Vol 238 ◽

pp. S244

Keyword(s):

Multiple Sclerosis ◽

Disease Severity ◽

Severity Score ◽

Cross Sectional

Download Full-text

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

Multiple Sclerosis Journal ◽

10.1177/1352458518819380 ◽

2018 ◽

Vol 26 (2) ◽

pp. 210-219 ◽

Cited By ~ 16

Author(s):

Heidi Högel ◽

Eero Rissanen ◽

Christian Barro ◽

Markus Matilainen ◽

Marjo Nylund ◽

...

Keyword(s):

Multiple Sclerosis ◽

Nervous System ◽

Glial Fibrillary Acidic Protein ◽

Disease Progression ◽

Disease Severity ◽

Single Molecule ◽

Progressive Disease ◽

Disease Duration ◽

Acidic Protein ◽

Csf Levels

Background: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression. Now, both biomarkers can be detected reliably in serum, and importantly, their serum levels correlate well with their CSF levels. Objective: To evaluate the usability of serum GFAP measurement as a biomarker of progressive disease and disease severity in MS. Methods: Clinical course, Expanded Disability Status Scale (EDSS), disease duration, patient age and magnetic resonance imaging (MRI) parameters were reviewed in 79 MS patients in this cross-sectional hospital-based study. Serum samples were collected for measurement of GFAP and NfL concentrations using single molecule array (Simoa) assay. A cohort of healthy controls was evaluated for comparison. Results: Higher serum concentrations of both GFAP and NfL were associated with higher EDSS, older age, longer disease duration, progressive disease course and MRI pathology. Conclusion: Earlier studies have demonstrated that GFAP, unlike NfL, is not increased in association with acute focal inflammation-related nervous system damage. Our work suggests that GFAP serum level associates with disease progression in MS and could potentially serve as an easily measurable biomarker of central nervous system (CNS) pathology related to disease progression in MS.

Download Full-text